STOCK TITAN

Quanterix Corp - QTRX STOCK NEWS

Welcome to our dedicated news page for Quanterix (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Quanterix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Quanterix's position in the market.

Rhea-AI Summary
Quanterix (QTRX) announces a new partnership path for laboratories interested in offering Tau-based research and diagnostic testing services. The company has secured over 30 U.S. patents, including one directed specifically to measuring Tau protein levels in biologic samples. Quanterix is focused on expanding clinical access to its leading blood biomarker assays in light of FDA approval of an Alzheimer's disease therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.67%
Tags
none
-
Rhea-AI Summary
Quanterix Corporation (QTRX) receives FDA Breakthrough Device designation for its p-Tau 217 blood test for Alzheimer's Disease diagnosis. The high-performing biomarker test aims to improve accessibility and accuracy in diagnosing AD, potentially revolutionizing patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
none
-
Rhea-AI Summary
Quanterix Corporation (NASDAQ: QTRX) reports strong financial results for Q4 and full year 2023, showcasing revenue growth, improved gross margins, and reduced net losses. The company's focus on research and diagnostics, along with strategic partnerships, positions it well for future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.69%
Tags
Rhea-AI Summary
Quanterix Corporation (NASDAQ: QTRX) reschedules financial results release for Q4 2023 and year-end, aligning with Form 10-K filing deadline. The investor call is now set for February 29, 2024. Revenue, gross margin, and cash usage expected to meet guidance. Conference call details and webcast information provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.67%
Tags
-
Rhea-AI Summary
Quanterix Corporation collaborates with leading health systems to enhance Alzheimer's disease diagnosis through innovative blood biomarker testing. The partnerships aim to provide non-invasive, accurate testing for patients across 140+ hospitals, benefiting approximately 21 million individuals in 18 states.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
-
Rhea-AI Summary
Quanterix Corporation (QTRX) CEO to present at Cowen's 44th Annual Health Care Conference. The session will focus on scientific discovery through ultrasensitive biomarker detection. The conference will be held from March 4 - 6, 2024, in Boston, MA, with webcast access available to the public.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
conferences
Rhea-AI Summary
Quanterix Corporation (NASDAQ: QTRX) will host a conference call on February 27, 2024, to discuss its fourth quarter earnings and full year 2023 financial results. The call will feature Masoud Toloue, President and CEO, and Vandana Sriram, CFO. The press release will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Quanterix Corporation (NASDAQ: QTRX) President and CEO Masoud Toloue to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.77%
Tags
conferences
-
Rhea-AI Summary
Quanterix Corporation (NASDAQ: QTRX) Announces CEO's Participation in Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. President and CEO Masoud Toloue will speak in a fireside chat on November 16, 2023, at 3:00 PM ET. The live webcast can be accessed by registering on the company's website, with a replay available afterward. This event aims to provide insights into the company's strategic direction and industry trends.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.47%
Tags
conferences
Rhea-AI Summary
Quanterix Corporation (NASDAQ: QTRX) reported its financial results for the third quarter of 2023. The company's revenue increased by 18% to $31.3 million compared to the same period last year. GAAP gross margin improved to 56.8% from 41.1% in the prior year period. Net loss for the quarter was $7.8 million, a significant decrease from $35.1 million in the corresponding prior year period. Quanterix also announced the launch of LucentAD p-Tau 217, a blood-based biomarker laboratory developed test for Alzheimer's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
Quanterix Corp

Nasdaq:QTRX

QTRX Rankings

QTRX Stock Data

699.23M
32.52M
8.72%
85.23%
2.63%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
United States
Billerica

About QTRX

quanterix offers an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. the single molecule array (simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at tufts university by dr. david walt, scientific founder of quanterix and illumina (nasdaq: ilmn).